Medtronic (NYSE:MDT) said today that it launched its Control Workflow system in the U.S. for use with its SynchroMed II intrathecal drug-delivery system.
The medtech titan is hoping that, combined with its pain pump, the workflow system can help physicians in weaning patients off oral opioids. In a retrospective claims analysis, Medtronic found that 51% of chronic non-malignant pain patients stopped using oral opioids after one year on the SynchroMed II pump.
Get the full story at our sister site, Drug Delivery Business News.